CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
doxorubicin hydrochloride +1 moredrug
Likely dose
gemcitabine hydrochloride 100mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00509665
NCT00509665Phase 2Completed
CompareCT.gov

A Phase II Study of Gemcitabine in Combination With Doxorubicin for Patients With Head and Neck Cancer

Medical University of South Carolina·interventional·Posted Jul 31, 2007·Updated Jul 12, 2018

In Brief

A Phase 2 clinical trial evaluating doxorubicin hydrochloride and gemcitabine hydrochloride for Head and Neck Cancer. Completed, enrolled 18 participants across 1 site.

Detailed Summary

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with doxorubicin works in treating patients with recurrent or progressive head and neck cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 31, 2007
Enrollment StartJun 1, 2005
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 18.9 years ago

Interventions

doxorubicin hydrochloridedrug

given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.

gemcitabine hydrochloridedrug

given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle